Blinatumomab consolidation for adults with B‑cell acute lymphoblastic leukemia
Real World Outcomes of Blinatumomab Consolidation in Patients With B-cell Acute Lymphoblastic Leukemia
This registry collects medical data on adults with B‑ALL who receive blinatumomab as consolidation to see how well it works and how safe it is in routine care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical College of Wisconsin Academic / other |
| Drugs / interventions | blinatumomab, inotuzumab, rituximab, chemotherapy |
| Locations | 1 site (Milwaukee, Wisconsin) |
| Trial ID | NCT07117136 on ClinicalTrials.gov |
What this trial studies
This is a multicenter registry that will collect both retrospective and prospective clinical data on adults with B‑cell acute lymphoblastic leukemia who receive blinatumomab during consolidation. Data entry and surveys will be managed through REDCap, a secure web application hosted by the Clinical & Translational Science Institute. The registry focuses on real‑world outcomes, including remission durability, relapse, minimal residual disease status, and safety/tolerability outside of controlled trials. Enrollment criteria specify adults aged 18 or older diagnosed on or after December 1, 2023, and exclude patients who received blinatumomab within an interventional clinical trial.
Who should consider this trial
Good fit: Adults aged 18 or older diagnosed with B‑cell ALL on or after December 1, 2023 who received blinatumomab as consolidation and did not receive blinatumomab in an interventional trial are ideal candidates.
Not a fit: Patients under 18, those diagnosed before December 1, 2023, or those treated with blinatumomab only within an interventional clinical trial are not eligible and would not directly benefit from joining this registry.
Why it matters
Potential benefit: If successful, the registry could show whether blinatumomab consolidation produces durable remissions and acceptable safety in real‑world adult B‑ALL patients.
How similar studies have performed: A randomized phase 3 trial (E1910) previously showed that adding blinatumomab during consolidation improved outcomes in selected adult patients, so this approach has demonstrated benefit in controlled trials.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\) aged 18 years or older 2) diagnosed with B-ALL on or after December 1st 2023 3) Not received blinatumomab in an interventional clinical trial setting 4) Willing and able to give informed consent (or retrospective data for deceased patients Exclusion Criteria: * N/A
Where this trial is running
Milwaukee, Wisconsin
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States (Recruiting)
Study contacts
- Study coordinator: Blong Vang
- Email: bvang@mcw.edu
- Phone: 4148056330
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.